Back to Search Results
Image Place holder

Pei-Ling Chen, MD, PhD


Specialty: Pathology
Program: Anatomic Pathology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)

Overview

Cancer Types Treated: Squamous Cell Carcinoma, Basal Cell Carcinoma , Melanoma , Merkel Cell Carcinoma , Skin Cancer (Nonmelanoma)

Dr. Pei-Ling Chen is an Assistant Member in the Moffitt Cancer Center Department of Anatomic Pathology. Dr. Chen received her MD from The Warren Alpert Medical School of Brown University in Providence, Rhode Island and her PhD from Stanford University, Department of Neurobiology/Program in Neurosciences. She completed a residency in anatomic pathology at Washington University in the Department of Pathology and Immunology/Barnes-Jewish Hospital in St. Louis, Missouri and a clinical fellowship in surgical pathology at the University of Texas MD Anderson Cancer Center in the Department of Pathology and Department of Genomic Medicine in Houston, Texas. Dr. Chen also completed a T32 postdoctoral research fellowship and a clinical fellowship in dermatopathology at the University of Texas MD Anderson Cancer Center. Her practice will be primarily in clinical dermatopathology.

Education & Training

Fellowship:

  • The University of Texas MD Anderson Cancer Center - Surgical Pathology
  • The University of Texas MD Anderson Cancer Center - T32 Postdoctoral Research Fellowship, Genomic Medicine
  • The University of Texas MD Anderson Cancer Center - Dermatopathology

Residency:

  • Washington University in St. Louis/Barnes-Jewish Hospital - Anatomic Pathology

Medical School:

  • The Warren Albert Medical School of Brown University - MD
  • Stanford University - PhD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN. A Preexisting Rare Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 May;8(5):556-567. Pubmedid: 29496665. Pmcid: PMC5932238.
  • Boddu P, Chen PL, Nagarajan P, Prieto VG, Won A, Chambers M, Kornblau S. Necrotizing fungal gingivitis in a patient with Acute Myelogenous Leukemia: visible yet obscure. J Oral Maxillofac Surg Med Pathol. 2018 Jan;30(1):50-54. Pubmedid: 29404266. Pmcid: PMC5796543.
  • Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 Jan;359(6371):97-103. Pubmedid: 29097493.
  • Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03;9(379). Pubmedid: 28251903. Pmcid: PMC5819607.
  • Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct;167(2):397-404.e9. Pubmedid: 27667683. Pmcid: PMC5088716.
  • Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb;6(2):202-216. Pubmedid: 26645196. Pmcid: PMC4744499.
  • Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08;6(8):827-837. Pubmedid: 27301722. Pmcid: PMC5082984.
  • Chen WS, Chen PL, Lu D, Lind AC, Dehner LP. Growth-associated protein 43 in differentiating peripheral nerve sheath tumors from other non-neural spindle cell neoplasms. Mod Pathol. 2014 Feb;27(2):184-193. Pubmedid: 23887302.
  • Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014 Dec;7(357):ra121. Pubmedid: 25538079. Pmcid: PMC4353587.
  • Chen WS, Chen PL, Li J, Lind AC, Lu D. Lipid synthesis and processing proteins ABHD5, PGRMC1 and squalene synthase can serve as novel immunohistochemical markers for sebaceous neoplasms and differentiate sebaceous carcinoma from sebaceoma and basal cell carcinoma with clear cell features. J Cutan Pathol. 2013 Jul;40(7):631-638. Pubmedid: 23557589.
  • Chen PL, Chen WS, Li J, Lind AC, Lu D. Diagnostic utility of neural stem and progenitor cell markers nestin and SOX2 in distinguishing nodal melanocytic nevi from metastatic melanomas. Mod Pathol. 2013 Jan;26(1):44-53. Pubmedid: 22899289.
  • Chen PL, Clandinin TR. The cadherin Flamingo mediates level-dependent interactions that guide photoreceptor target choice in Drosophila. Neuron. 2008 Apr;58(1):26-33. Pubmedid: 18400160. Pmcid: PMC2494600.
  • Bazigou E, Apitz H, Johansson J, Lorén CE, Hirst EM, Chen PL, Palmer RH, Salecker I. Anterograde Jelly belly and Alk receptor tyrosine kinase signaling mediates retinal axon targeting in Drosophila. Cell. 2007 Mar;128(5):961-975. Pubmedid: 17350579.
  • Mast JD, Prakash S, Chen PL, Clandinin TR. The mechanisms and molecules that connect photoreceptor axons to their targets in Drosophila. Semin Cell Dev Biol. 2006 Feb;17(1):42-49. Pubmedid: 16337412.
  • Lee RC, Clandinin TR, Lee CH, Chen PL, Meinertzhagen IA, Zipursky SL. The protocadherin Flamingo is required for axon target selection in the Drosophila visual system. Nat Neurosci. 2003 Jun;6(6):557-563. Pubmedid: 12754514.